Literature DB >> 17075015

Calcific aortic valve stenosis in old hypercholesterolemic mice.

Robert M Weiss1, Masuo Ohashi, Jordan D Miller, Stephen G Young, Donald D Heistad.   

Abstract

BACKGROUND: Hypercholesterolemia and old age are clinical risk factors for development of aortic valve stenosis, and hypercholesterolemia is a putative therapeutic target. We tested the hypothesis that calcification and aortic valve stenosis would develop in genetically hypercholesterolemic old mice. METHODS AND
RESULTS: Twenty-four low-density lipoprotein receptor-deficient apolipoprotein B-100-only (LDLr(-/-)ApoB(100/100)) mice were fed normal chow from weaning until age 20.1+/-0.5 months (mean+/-SE; range 17 to 22 months). Twenty-one age-matched (20.8+/-0.9 months, range 17 to 25 months) C57Bl/6 mice served as controls. Echocardiographic imaging was used to assess morphology and function of the aortic valve and left ventricle. A subset of 12 mice underwent invasive hemodynamic assessment of aortic valve function. Functionally significant aortic stenosis, with >75% reduction in valve area, occurred in 8 of 24 LDLr(-/-)ApoB(100/100) mice and in 0 of 21 controls (P=0.01). In the subset that underwent catheterization, mice with echocardiographic evidence of aortic stenosis had a systolic transvalvular gradient of 57+/-6 mm Hg. In the group of all LDLr(-/-)ApoB(100/100) mice with aortic stenosis, left ventricular mass was increased by 67% (P=0.001) and ejection fraction was decreased by 30% (P=0.004) compared with LDLr(-/-)ApoB(100/100) without aortic stenosis. Von Kossa staining of the aortic valve demonstrated abundant mineralization in LDLr(-/-)ApoB(100/100) mice but not in control mice. Superoxide (oxyethidium fluorescence) was present in valve tissue from all 3 groups of mice and was more abundant in mice with aortic stenosis.
CONCLUSIONS: Hypercholesterolemic LDLr(-/-)ApoB(100/100) mice are prone to develop calcification and oxidative stress in the aortic valve, with functional valvular heart disease, mimicking the clinical syndrome. This discovery holds promise for elucidation of the pathophysiology of aortic valve disease mechanisms and for the design of effective nonsurgical treatment.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17075015     DOI: 10.1161/CIRCULATIONAHA.106.634139

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  87 in total

1.  Cholesterol in vascular and valvular calcification.

Authors:  L L Demer
Journal:  Circulation       Date:  2001-10-16       Impact factor: 29.690

2.  Activation of vascular smooth muscle parathyroid hormone receptor inhibits Wnt/beta-catenin signaling and aortic fibrosis in diabetic arteriosclerosis.

Authors:  Su-Li Cheng; Jian-Su Shao; Linda R Halstead; Kathryn Distelhorst; Oscar Sierra; Dwight A Towler
Journal:  Circ Res       Date:  2010-05-20       Impact factor: 17.367

3.  Transcriptional and phenotypic changes in aorta and aortic valve with aging and MnSOD deficiency in mice.

Authors:  Carolyn M Roos; Michael Hagler; Bin Zhang; Elise A Oehler; Arman Arghami; Jordan D Miller
Journal:  Am J Physiol Heart Circ Physiol       Date:  2013-08-30       Impact factor: 4.733

Review 4.  Calcific aortic valve disease: not simply a degenerative process: A review and agenda for research from the National Heart and Lung and Blood Institute Aortic Stenosis Working Group. Executive summary: Calcific aortic valve disease-2011 update.

Authors:  Nalini M Rajamannan; Frank J Evans; Elena Aikawa; K Jane Grande-Allen; Linda L Demer; Donald D Heistad; Craig A Simmons; Kristyn S Masters; Patrick Mathieu; Kevin D O'Brien; Frederick J Schoen; Dwight A Towler; Ajit P Yoganathan; Catherine M Otto
Journal:  Circulation       Date:  2011-10-18       Impact factor: 29.690

5.  Calcific aortic stenosis: a disease ready for prime time.

Authors:  Nalini M Rajamannan
Journal:  Circulation       Date:  2006-11-07       Impact factor: 29.690

6.  Decorin and biglycan retain LDL in disease-prone valvular and aortic subendothelial intimal matrix.

Authors:  Edward B Neufeld; Leah M Zadrozny; Darci Phillips; Angel Aponte; Zu-Xi Yu; Robert S Balaban
Journal:  Atherosclerosis       Date:  2014-01-08       Impact factor: 5.162

Review 7.  Adaptive immune cells in calcific aortic valve disease.

Authors:  Michael A Raddatz; Meena S Madhur; W David Merryman
Journal:  Am J Physiol Heart Circ Physiol       Date:  2019-05-03       Impact factor: 4.733

8.  A dynamic pathway for calcium-independent activation of CaMKII by methionine oxidation.

Authors:  Jeffrey R Erickson; Mei-ling A Joiner; Xiaoqun Guan; William Kutschke; Jinying Yang; Carmine V Oddis; Ryan K Bartlett; John S Lowe; Susan E O'Donnell; Nukhet Aykin-Burns; Matthew C Zimmerman; Kathy Zimmerman; Amy-Joan L Ham; Robert M Weiss; Douglas R Spitz; Madeline A Shea; Roger J Colbran; Peter J Mohler; Mark E Anderson
Journal:  Cell       Date:  2008-05-02       Impact factor: 41.582

9.  Endothelial nitric oxide signaling regulates Notch1 in aortic valve disease.

Authors:  Kevin Bosse; Chetan P Hans; Ning Zhao; Sara N Koenig; Nianyuan Huang; Anuradha Guggilam; Stephanie LaHaye; Ge Tao; Pamela A Lucchesi; Joy Lincoln; Brenda Lilly; Vidu Garg
Journal:  J Mol Cell Cardiol       Date:  2013-04-11       Impact factor: 5.000

10.  Diabetes increases mortality after myocardial infarction by oxidizing CaMKII.

Authors:  Min Luo; Xiaoqun Guan; Elizabeth D Luczak; Di Lang; William Kutschke; Zhan Gao; Jinying Yang; Patric Glynn; Samuel Sossalla; Paari D Swaminathan; Robert M Weiss; Baoli Yang; Adam G Rokita; Lars S Maier; Igor R Efimov; Thomas J Hund; Mark E Anderson
Journal:  J Clin Invest       Date:  2013-02-15       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.